Document is current
Any future updates will be listed below
-
Authors
Kennedy, Patrick H.
Alborzian Deh Sheikh, Amin
Balakar, Matthew
Jones, Alexander C.
Olive, Meagan E.
Hegde, Mudra
Matias, Maria I.
Pirete, Natan
Burt, Rajan
Levy, Jonathan
Little, Tamia
Hogan, Patrick G.
Liu, David R.
Doench, John G.
Newton, Alexandra C.
Gottschalk, Rachel A.
de Boer, Carl G.
Alarcón, Suzie
Newby, Gregory A.
Myers, Samuel A.
- License Information
-
More Information
Article History
Received: 16 October 2023
Accepted: 20 March 2024
First Online: 29 April 2024
Competing interests
: D.R.L. is a consultant and/or equity owner for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine and Nvelop Therapeutics—companies that use or deliver genome editing or epigenome engineering agents. The other authors declare no competing interests.
